Palatin Technologies

OverviewSuggest Edit

Palatin Technologies is a biopharmaceutical company, developing targeted, receptor-specific peptide therapeutics for the treatment of various diseases. The Company’s principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder. Its drug development programs also include melanocortin peptide system program, including PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation.

TypePublic
Founded1986
HQCranbury Township, USMap
Websitepalatin.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Sep 2019)18(-5%)
Revenue (FY, 2015)$13 M
Share Price (Jun 2019)$1.3 (+4%)

Key People/Management at Palatin Technologies

Carl Spana

Carl Spana

President and Chief Executive Officer
Johna Lucas

Johna Lucas

Chief Medical Officer
Stephen Wills

Stephen Wills

Executive Vice President, Chief Financial Officer and Chief Operating Officer
Show more

Palatin Technologies Office Locations

Palatin Technologies has an office in Cranbury Township
Cranbury Township, US (HQ)
4b Cedarbrook Dr, Cranbury
Show all (1)

Palatin Technologies Financials and Metrics

Palatin Technologies Revenue

Palatin Technologies's revenue was reported to be $12.95 m in FY, 2015
USD

Net income (FY, 2019)

35.8m

EBIT (FY, 2019)

35.7m

Market capitalization (10-Jun-2019)

262.0m

Closing stock price (10-Jun-2019)

1.3

Cash (30-Jun-2019)

43.5m

EV

218.8m
Palatin Technologies's current market capitalization is $262 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

13.0m

Revenue growth, %

(100%)

General and administrative expense

5.0m5.7m6.2m9.6m8.6m9.7m

R&D expense

10.8m24.6m43.1m45.7m32.6m14.9m
Quarterly
USDQ1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

4.9m8.0m10.8m

General and administrative expense

1.0m980.1k1.1m1.4m1.1m1.2m1.4m1.4m1.2m1.3m4.8m1.5m1.6m2.4m2.0m2.1m1.8m

R&D expense

3.4m2.6m2.9m4.3m7.6m10.6m11.3m10.7m11.2m8.1m9.1m14.2m6.0m7.1m3.6m3.0m3.9m

Operating expense total

4.5m3.6m4.0m5.7m8.7m11.8m12.6m12.1m12.4m9.4m13.8m15.7m7.7m9.5m5.7m5.1m5.8m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

12.2m27.3m8.0m40.2m38.0m43.5m

Accounts Receivable

5.5m15.1m60.3m

Inventories

156.4k1.9m1.4m

Current Assets

12.3m29.2m10.8m56.6m38.5m104.4m
Quarterly
USDQ1, 2014Q2, 2014Q1, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

18.6m16.7m17.8m47.5m32.0m21.8m8.9m12.1m54.5m39.7m35.0m25.7m32.6m24.7m19.8m

Accounts Receivable

4.7m9.4m104.2k

Current Assets

22.6m18.5m18.3m49.3m35.1m24.6m11.3m14.3m61.2m50.3m36.2m26.4m33.1m25.2m20.5m

PP&E

245.4k216.1k133.2k130.2k118.7k107.6k90.2k82.5k74.9k193.0k178.8k165.1k150.0k136.2k156.6k
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(13.9m)(17.7m)(51.7m)(13.3m)24.7m35.8m

Depreciation and Amortization

111.9k117.6k43.1k33.1k56.6k58.6k

Inventories

Accounts Payable

(77.4k)845.2k(392.6k)837.5k672.3k(1.7m)
Quarterly
USDQ1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(4.5m)(8.1m)794.7k3.6m(5.6m)(12.4m)(25.7m)(38.4m)(13.1m)(23.1m)(26.6m)10.6m13.6m12.9m(5.7m)(10.7m)(16.5m)

Depreciation and Amortization

27.2k56.6k27.6k55.2k86.8k10.7k22.2k33.2k7.6k15.3k22.9k14.6k28.9k42.6k14.0k27.9k43.5k

Accounts Payable

652.2k(47.7k)300.1k1.2m2.1m2.2m1.3m676.8k445.5k4.0m529.3k482.3k(847.6k)(757.7k)(1.1m)(1.6m)(1.7m)

Cash From Operating Activities

(2.0m)(6.2m)5.7m1.4m(3.9m)(9.4m)(23.4m)(33.7m)(6.6m)(17.7m)25.8m1.4m(1.6m)(8.8m)(5.5m)(11.0m)(14.8m)
show all
USDY, 2019

EV/EBIT

5.6 x

EV/CFO

-9.2 x
Show all financial metrics

Palatin Technologies Online and Social Media Presence

Palatin Technologies's Trends

Embed Graph

Palatin Technologies News and Updates

September 12, 2019

Thinking about buying stock in Canopy Growth, Micron Technology, Palatin Technologies, SINTX Technologies, or Tilray?

NEW YORK, Sept. 12, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, MU, PTN, SINT, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
September 12, 2019

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2019 Results

CRANBURY, N.J., Sept. 12, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, whose...
June 24, 2019

Thinking about buying stock in Aurora Cannabis, AMAG Pharmaceuticals, Minerva Neurosciences, Palatin Technologies, or Zoom Video Communications?

NEW YORK, June 24, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, AMAG, NERV, PTN, and ZM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
June 06, 2019

Palatin Technologies Granted FDA Orphan Drug Designation -- PL-8177 for the Treatment of Non-Infectious Uveitis

CRANBURY, N.J., June 6, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced ...
May 03, 2019

Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on May 9, 2019

CRANBURY, N.J., May 3, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2019 operating results on Thursday, May 9, 2019 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live...
April 04, 2019

Palatin Technologies Announces Positive Top Line Results of Oral Clinical Study of PL-8177 for Ulcerative Colitis and Other Inflammatory Bowel Diseases

CRANBURY, N.J., April 4, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today...
Show more

 Palatin Technologies Frequently Asked Questions

  • When was Palatin Technologies founded?

    Palatin Technologies was founded in 1986.

  • Who are Palatin Technologies key executives?

    Palatin Technologies's key executives are Carl Spana, Johna Lucas and Stephen Wills.

  • How many employees does Palatin Technologies have?

    Palatin Technologies has 18 employees.

  • Who are Palatin Technologies competitors?

    Competitors of Palatin Technologies include Immunicum, Ventria Bioscience and Biotec Pharmacon.

  • Where is Palatin Technologies headquarters?

    Palatin Technologies headquarters is located at 4b Cedarbrook Dr, Cranbury, Cranbury Township.

  • Where are Palatin Technologies offices?

    Palatin Technologies has an office in Cranbury Township.

  • How many offices does Palatin Technologies have?

    Palatin Technologies has 1 office.